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Abstract  
 Drug/polymer interactions occur during in situ polymerization of 
poly(alkylcyanoacrylate) (PACA) formulations.  We have used MALDI ionization coupled 
tandem time-of-flight (TOF) mass spectrometry as an accurate method to characterize covalent 







]-angiotensin II, and fragments of insulin-like growth factor 1 (IGF-1 (1-3)) and 
human adrenocorticotropic hormone (h-ACTH, (18-39)) at the molecular level.  Covalent 













]-angiotensin II were 
modified at their histidine side chain within the peptide, whilst IGF-1 (1-3) was modified at the 
C-terminal glutamic acid residue.  The more complex protein insulin did not co-polymerize 
despite the presence of 2 histidine residues.  This might be explained by the engagement of 
histidine residues in the folding and sterical arrangement of insulin under polymerization 
conditions.  As expected, h-ACTH (18-39) that does not contain histidine residues did not co-
polymerize.  Lowering the pH did not prevent the co-polymerization of PACA with D-Lys
6
-
GnRH or IGF-1 (1-3).  Conclusively, protein and peptide bioactives are potentially reactive 
towards PACA nanoparticles via various mechanisms with limited interference of pH.  
Histidines and C-terminal glutamic acid residues have been identified as potential sites of 
interaction.  The likelihood of their engagement in co-polymerization, however, seems 
dependant on their sterical availability.  The potential for co-polymerization should be 
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considered when designing a PACA delivery system for protein and peptide 
biopharmaceuticals. 
 





Poly(alkylcyanoacrylate) (PACA) nanoparticles appeal to formulation scientists for a 
number of reasons.  Their potential to incorporate both hydrophobic and hydrophilic 
compounds by utilizing different preparation techniques renders them applicable to a wide 
range of drugs [1, 2].  The number of protein and peptide drugs is increasing as the sector of 
modern biopharmaceuticals is growing, demanding pharmaceutical formulations capable of 
ensuring their safety, stability and bioactivity [3].  High entrapment efficiencies (~85%) of 
peptide bioactives, such as insulin [4, 5] and calcitonin [6] have been achieved using the 
anionic interfacial polymerization technique to produce PACA nanoparticles.  Using 
biodegradable and biocompatible w/o-microemulsions as polymerization templates is 
particularly beneficial for PACA formulations with peroral applications since microemulsions 
exhibit permeation enhancing properties [7].  Comprehensive reviews on their biomedical 
applications as controlled drug delivery systems are available elsewhere [1-3, 8]. 
 
The formation of polymeric nanoparticles by anionic interfacial polymerization is 
usually initiated by slowly adding monomer to the polymerization template (e.g. a w/o-
microemulsion).  The hydroxyl ions arising from the autoprotolysis of water are believed to be 
the main reaction initiators for the anionic reaction pathway [1, 9].  In situ polymerization 
requires all ingredients, including both the monomer and the drug, to be present during the 
polymerization step.  Thus, the drug has the potential to interfere with the polymerization 
process.  For some polymeric PACA systems produced by in situ polymerization, incomplete 
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release (less than 80%) of bioactive was suggested to be indicative of strong drug-polymer 
interactions causing certain drug fractions to remain unreleased [10, 11].  The release of a 
gonadotropin releasing hormone (GnRH) analogue from poly(ethylcyanoacrylate) (PECA) 
nanoparticles was as low as 10% when incubated in phosphate buffer pH 7.4 for several days 
[12].  Such release characteristics may impair the bioavailability and effectiveness of the drug, 
depending on therapeutic doses and action onset times required.  However, covalent association 
of drug with polymer (co-polymerization) may also function as a means to produce sustained 
and controlled release delivery systems with slow release profiles.  Previous research has 
involved the deliberate functionalization of bioactives in order to add a reactive entity capable 
of covalently interfering with the polymerization process, such as the addition of vinyl acetate 
to the bioactive GnRH [13] or the addition of an acryloyl-functional group to the antigenic 
epitope of the lymphocytic choriomeningitis virus glycoprotein (LCMV33-41) [9].  The 
resulting co-polymerized systems demonstrated improved stability of the bioactive in 
physiological fluids [13] and prolonged slow-release characteristics via bioerosion [14].  
Therefore, such co-polymerized nanoparticulate delivery systems seem particularly suitable for 
sustained drug delivery, such as delivery of vaccines [15]. 
 
Methods employed to investigate the phenomenon of co-polymerization in PACA 
nanoparticles include (i) size exclusion chromatography (SEC), more specifically gel 
permeation chromatography (GPC) [14] and (ii) thin-layer chromatography (TLC) [11].  
Chemical modification of polymer fractions were inferred due to (i) the occurrence of an earlier 
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eluting fraction (i.e. larger size) causing a shoulder peak in the GPC profile compared to a 
reference chromatogram obtained by a physical mixture of preformed polymer and drug [14] 
and (ii) the occurrence of additional bands in the thin-layer chromatogram compared to 
reference bands of empty polymers, drug alone or a physical mixture of drug and polymer [11].  
These methods, however, have a number of limitations.  Both chromatographic methods 
separate the analytes according to bulk characteristics, such as the hydrodynamic volume 
(SEC) or affinity of the analyte towards certain surfaces (e.g. silica-grafted surfaces as in TLC).  
The detection of signals based on the refractive index of eluents in SEC or UV-Vis 
visualization of bands in TLC are unselective and molecular species co-eluting at the same will 
contribute to the same signal/band in the chromatogram.  Unambiguous identification of 
analytes is lacking in these methods.  Furthermore, in order to interpret a chromatogram, 
reference chromatograms are required.  Depending on the preparation of reference samples, 
physical mixtures of preformed PACA nanoparticles and drug may still retain the potential to 
form covalent drug-polymer bonds whilst in the liquid phase.  In our recent studies, we have 
demonstrated the potential of a GnRH-analogue to co-polymerize with PECA nanoparticles 
when added 4 hours after the polymerization reaction was completed (ex situ addition) [12].  
Interpretations of reference chromatograms with the assumption that no peptide-polymer 
interactions occur in a physical mixture can lead to misinterpretations. 
 
We recently employed matrix-assisted laser desorption/ionization tandem time-of-flight 
mass spectrometry (MALDI TOF/TOF MS) in combination with collision-induced dissociation 
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(CID) to characterize covalent interactions of PECA nanoparticles with D-Lys
6
-GnRH after in 
situ and ex situ polymerization [12].  MALDI coupled TOF/TOF MS proved to be particularly 
suitable for the analysis of peptide/PECA co-polymers in the presence of excess PECA 
polymer.  In MALDI, a soft ionization method that enables the measurement of large intact 
biomolecules and polymers, samples are co-crystallized with excess matrix, a compound that is 
activated upon absorption of laser energy.  A mixture of activated matrix (here a cinnamic acid 
derivative) and analyte is vaporized and transferred into the gaseous phase where a proton 
transfer between activated matrix and analyte occurs yielding mostly singly charged ions (z = 
1).  Prerequisite for MALDI ionization is the ability of an analyte to donate or accept protons 
from a given matrix.  D-Lys
6
-GnRH and its conjugated co-polymers showed a very efficient 
ionization, while ionization of PECA polymers was strongly suppressed.  The covalent 
interaction of the histidine residue in D-Lys
6
-GnRH with PECA was identified unambiguously 
by CID-based tandem TOF MS.  In the first TOF analysis, accurate masses of unmodified 
peptide and molecular species shifted by a multiple of 125 mass units corresponding to the 
mass of PECA monomers were detected.  The site of interaction was then analyzed by mass 
measurements of fragment ions after collision induced dissociation of selected co-polymers.  
Mass spectrometry of CID-based ion fragments reveals sequence information and information 
about sites of amino acid modifications. 
 
In the present study we extend our previous work to gain a more detailed insight into 
the possible reaction mechanisms involved.  Using MALDI TOF/TOF MS in combination with 
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CID we investigate a range of histidine-containing and non-histidine-containing bioactive 
peptides on their capability to covalently interfere in the polymerization process of different 
poly(alkylcyanoacrylates), namely ethyl- and butylcyanoacrylate.  We further tested how the 
pH, hence ionization status of peptides at the time of polymerization, influences the co-










GlyNH2) was purchased from PolyPeptide Laboratories (Torrance, CA, USA).  The 









purchased from Sigma-Aldrich Inc. (St Louis, MO, USA).  The commercially available 
Humulin® R (Eli Lilly Australia Pty. Limited, NSW, AU) contains 100 IU/ml recombinant 
human insulin, stabilized by m-cresol and glycerol at a pH of 7.4.  Humulin® R solution was 
concentrated 2.5 times using a centrifugal vacuum concentrator (Savant SpeedVac Plus SC 210 
A).  IGF-1 (1-3) fragment (Gly-Pro-Glu) was purchased from Bachem AG (Bubendorf, CH).  
The peptide fragment (18-39) of human adrenocorticotropic hormone (h-ACTH) (Arg-Pro-Val-
Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe) was 
purchased from Sigma-Aldrich (St Louis, MO, USA).  The monomers ethylcyanoacrylate 
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(ECA) (Sicomet 40) and butylcyanoacrylate (BCA) (Sicomet 6000) were kindly donated by 
Henkel Loctite (Hannover, Germany).   
For preparation of microemulsions, the oil component ethyloleate GPR was sourced 
from BDH Laboratory Supplies (Poole, England) and the surfactants sorbitan monolaurate 
(Crill 1) and ethoxy 20 sorbitan mono-oleate (Crillet 4) were kindly provided by BTB 
Chemicals (Auckland, New Zealand).  Methanol (HPLC grade), chloroform, acetonitrile 
(HPLC grade) and hydrochloric acid (fuming 37%, GR for analysis) were obtained from Merck 
KGaA (Darmstadt, Germany).  Ethanol was supplied by AnchorEthanol (Auckland, New 
Zealand).  Distilled, ultra-pure water was obtained from a Milli-Q water Millipore Purification 
System (USA) and was used at all times during sample preparation. 
 
2.2. Preparation of PECA nanoparticles from a microemulsion template  
 
For preparation of a microemulsion template, we followed the method of 
Watnasirichaikul et al. [4] mixing water, oil and a surfactant-blend together at a 1 : 3.6 : 5.4 
weight ratio.  Beforehand, the surfactants Crill 1 and Crillet 4 were mixed in a 4 : 6 weight ratio 
to form the surfactant-blend.  The bioactive peptides (D-Lys
6





]-angiotensin II and h-ACTH (18-39)) were each dissolved in the water phase prior 
to mixing with the other microemulsion ingredients.  Important peptide characteristics and 
amounts of peptides used in this study are given in Table 1.  Distilled, ultrapure water had a pH 
of 6.3 and was adjusted for studying the influence of pH to 1.9 with hydrochloric acid.  
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Microemulsion formation occurred instantly upon stirring at 700 rpm at 4°C.  10 g of 
microemulsion was polymerized with 200 µl ECA monomer dissolved in 600 µl of chloroform.  
The monomer was added slowly to the microemulsion template under continuous stirring at 
700 rpm at 4°C.  After the addition of monomer, the mixture was left overnight to complete the 
polymerization process and to evaporate the chloroform. 0.5 g of formulation was mixed with 
2.5 ml ultrapure water pH 2.5 (pH adjusted with hydrochloric acid).  An aliquot of 600 µl was 
withdrawn and mixed with 600 µl methanol 80% (v/v, water pH 2.5) allowing for the 
separation of nanoparticles from the surrounding microemulsion by centrifugation at 20,800 g 
and 25°C for 20 min (Eppendorf Centrifuge 5415C).  Nanoparticles were subsequently washed 
twice with in ethanol (abs.) to remove residual oil and surfactants.  Isolated nanoparticles were 
characterized using MALDI TOF MS/MS the day after polymerization. 
 
Table 1. Relevant formulation and peptide characteristics  
 
 
2.3. MALDI TOF mass spectrometry 
 
Freshly prepared and washed nanoparticles were dissolved in approximately 20-40 µl 
acetonitrile and 1.0 µl of sample solution was mixed with 9.0 µl of matrix (10 mg/ml alpha 
cyano-4-hydroxycinnamic acid dissolved in 60% (v/v) aqueous acetonitrile containing 0.1% 
(v/v) trifluoroacetic acid).  An aliquot of 0.8 µl was spotted onto the MALDI-plate (Opti-TOF 
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384 well plate, Applied Biosystems, MA, USA) and air-dried.  Samples were analyzed on a 
4800 MALDI tandem Time-of-Flight Analyzer (Applied Biosystems, MA, USA).  The default 
calibration for each operation mode was updated on six calibration spots.  All MS spectra were 
acquired in positive-ion reflector mode with 1000 laser pulses per sample spot. 
Co-polymers were identified by the presence of mass signals [M + (P)n + H]
+
, 
corresponding to parent peptide mass [M + H]
+
 being shifted by a certain number of polymer 
increments (P)n.  To identify the amino acid involved in peptide/PECA or PBCA interaction co-
polymer precursor ions were selected for collision induced dissociation tandem mass 
spectrometry (CID-MS/MS).  CID-MS/MS spectra were acquired with 2000-4000 laser pulses 
per selected precursor using the 2 kV mode.  Air was used as collision gas at a pressure of 1⋅10
-
6 
torr.  CID-MS/MS spectra were interpreted manually as described previously [12] mainly 
considering b-, y- and a-type ions as well as relevant immonium ions according to the Biemann 
nomenclature [16]. 
 
Table 2. Summary of peptide co-polymerization with ethyl- and butylcyanoacrylate 
 
 
3.  RESULTS 




 Three of the five bioactive peptides investigated were found to co-polymerize with both 
ethyl-and butylcyanoacrylate (Table 2).  Co-polymerization was determined by the occurrence 
of co-polymer signals [M + (P)n + H]
+
 in the MS spectra for all three peptides (Fig. 1a-c).  
MS/MS spectra were recorded for selected co-polymer precursor-ions in order to identify the 
site of modification within the peptide molecule (Table 2).  Relevant spectra of modified 
histidine- and non-histidine-containing peptides are discussed in more detail in the following 
sections. 
 







]-angiotensin II and insulin) 
 
The previously identified reactivity of D-Lys
6
-GnRH to co-polymerize with 
ethylcyanoacrylate [12] was also demonstrated for butylcyanoacrylate (Fig. 1a).  Unmodified 
D-Lys
6
-GnRH gave a peak at m/z 1253.6 [M + H]
+
, which indicated that the peptide within the 
PBCA nanoparticles existed, in part, in the free form.  Relative to the mass of the free peptide 
[M + H]
+
, co-polymers of D-Lys
6
-GnRH with PBCA were shifted by a multiple of monomer 
subunits (153)n (m/z 1559.8 for 2, m/z 1712.9 for 3, m/z 1866.0 for 4, m/z 2019.1 for 5, m/z 
2172.1 for 6, etc.).  CID-MS/MS on selected precursor ions of co-polymers revealed the 
histidine residue in position 2 of D-Lys
6










]-angiotensin II, another small histidine-containing peptide, also co-





]-angiotensin II recorded for PECA and PBCA are shown in Fig. 1b, and 1c 






]-angiotensin II entrapped 
within the polymeric nanoparticles was identified at m/z 1031.5 [M + H]
+
.  Co-polymers were 
detected as a series of ions shifted either by increments of 125 mass units for ECA (Fig. 1b) or 
153 mass units for BCA (Fig. 1c).  Precursor ions (*) of the peptide/PECA co-polymer series at 
m/z 1406.7, 1531.7 and 1656.8 corresponding to [M + (125)3-5 + H]
+
 were selected for CID-





 CID-based fragmentation of co-polymers yielded dissociation of peptide (m/z 1031.5) 
from polymer as well as sequential loss of monomer subunits [Precursor – (P)n]
+
 (Fig. 2a-c).  





angiotensin II co-polymerized with 5 monomers [1030.5 + (125)5 + H]
+
 (Fig. 1b) shows the 
loss of 1 (m/z 1531.7), 2 (m/z 1406.7), 3 (m/z 1281.6) and 5 (m/z 1031.5) monomer subunits 
(Fig. 2c).  CID-based fragmentation of the peptide backbone revealed information of the site of 
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polymer addition to the peptide.  A clear signal of modified histidine immonium ions identified 
the histidine residue as the site of modification (Fig. 2a-c).  Amino acid-specific immonium 
ions are low mass fragment ions that are generated by multiple cleavage events and contain 
only a single amino acid side chain.  Such immonium ions can be used as diagnostic ions to 
confirm the presence of certain amino acids.  Histidines usually generate strong signals of their 





polymers, the histidine immonium ion was shifted by the mass corresponding to the number of 
PECA monomers associated with the peptide.  For example, histidine immonium ions in CID 
spectra of precursors (*) m/z 1406.7 [1030.5 + (125)3 + H]
+
, 1531.7 [1030.5 + (125)4 + H]
+
 and 
1656.8 [1030.5 + (125)5 + H]
+
 appeared at m/z 485.2 [110 + (125)3]
 +
(Fig. 2a), m/z 610.3 [110 
+ (125)4]
 +
(Fig. 2b), and m/z 735.3 [110 + (125)5]
 +
 (Fig. 2c).  No other amino acid was found 
to be modified.  This confirms the histidine residue in position 6 of the peptide molecule is the 





]-angiotensin II/PBCA co-polymers (data not shown). 
 
In contrast to the small histidine-containing peptides tested here, no co-polymerization 
was observed when the more complex, histidine-containing protein insulin was polymerized 
with PECA nanoparticles.  The MS spectrum showed signals for the doubly charged (m/z 
2904.4 for z = 2 [M + 2H]
2+
) and singly charged (m/z 5805.1 for z = 1 [M + H]
+
) insulin and an 
independent series of peaks with characteristic peak increments of 125 mass units over the 
mass range m/z 700-6000 for PECA polymers (Fig. 1d).  Peaks corresponding to co-polymers 
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[M + (125)n + H]
+
 were absent indicating that no residue interfered in the polymerization 
process.  Similarly, no co-polymers were obtained when insulin was polymerized with 





3.1.2. Non-histidine-containing peptides with ethyl-and butylcyanoacrylate (h-ACTH (18-
39), IGF-1 (1-3)) 
 
The non-histidine containing peptide h-ACTH (18-39) did not co-polymerize with 
PECA.  The MS spectrum of h-ACTH (18-39) polymerized with PECA nanoparticles showed a 
clear signal of the parent molecule at m/z 2465.6 [M + H]
+
 (Fig. 3a) and an independent series 
of PECA polymer peaks with characteristic peak increments of 125 mass units over the mass 
range m/z 1000-4000 (Fig. 3a).  Peaks corresponding to co-polymers [M + (125)n + H]
+
 were 
absent.  Similarly, no co-polymers were obtained when h-ACTH (18-39) polymerized with 
butylcyanoacrylate (data not shown). 
 
Interestingly IGF-1 (1-3), another non-histidine containing peptide co-polymerized with 
PECA indicated by a series of signals at m/z 802.3, 927.4, 1052.4 and 1177.5 [301.3 +(125)4-7 
+ H]
+




 (Fig. 3b).  CID-MS/MS on IGF-1(1-3)/PECA co-polymers (*) [301.3 + (125)4-6 + 
H]
+
 revealed clear signals of unmodified b2-ions (Gly-Pro) at m/z 155.1 for all three precursors 
selected (Fig. 4a-c).  The modification was located on the y-ion series as indicated by y1-and 





3.2. Influence of pH on co-polymerization of peptides 
 
 We investigated whether a very low pH may impede the co-polymerization of D-Lys
6
-
GnRH and IGF-1 (1-3) with PECA during the in situ interfacial polymerization of PACA 
nanoparticles.  Both peptides co-polymerized with PECA at pH 1.9 as indicated by MS-signals 




-GnRH/PECA co-polymers (Fig. 5a) and [301.3 + (125)4-
7 + H]
+
 for IGF-1 (1-3)/PECA co-polymers (Fig. 5b).  CID-MS/MS on both peptide co-
polymers confirmed that the same residues were involved in the co-polymerization at pH 6.3 






4.  DISCUSSION 
 







]-angiotensin II co-polymerize with both ethyl- and butylcyanoacrylate (Fig. 1a-c), 
which confirms our previous findings of covalent interaction of His2 of D-Lys
6
-GnRH with 
ethylcyanoacrylate [12].  In both peptides, we identified the histidine residue as the site of 
modification (Fig. 2).  The longer and slightly bulkier butyl-ester side chain of the butyl-
monomer did not impair the ability of the nucleophilic peptide to attack the acrylate ethylene-
group of the monomer.  Protonation of the nucleophilic histidine at pH 1.9 also did not impede 
co-polymerization of D-Lys
6
-GnRH with PECA nanoparticles (Fig. 5a).  Although more 
protonated, hence less nucleophilic histidine residues (pKa 6.04) are present at pH 1.9, the few 
remaining were reactive enough to initiate the polymerization reaction (zwitter-ionic pathway).  
A rapid elongation and termination reaction yields insoluble peptide/polymer co-polymers, 
which precipitate and aggregate to form nanoparticles.  This results according to Le Chatelier’s 
principle, in a shift of the equilibrium between protonated and unprotonated histidine, re-
generating new unprotonated nucleophiles maintaining the reaction until completion. 
 
The mere presence of histidine as a nucleophile alone, however, is not sufficient to 
initiate co-polymerization.  From this study, the sterical availability of the nucleophile seems to 
be another important key factor to influence on the reaction, since insulin despite the presence 




) did not co-polymerize (Fig. 1d). 
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Fig. (6)  
 







]-angiotensin II.  In the literature, the three dimensional 
arrangement and folding of insulin is extensively discussed considering various aspects that 
may influence on the confirmation of insulin [19-22].  Depending on the insulin concentration, 
pH and presence of ligands, insulin shows a tendency to self-associate into insulin dimers or 
hexamers [19, 20].  The influence of phenols, such as m-cresol, is mainly discussed in the 
context of hexameric insulin, which forms in the presence of divalent cations, such as zinc.  
Zinc, however, is not present in our current study.  We suggest that under polymerization 
conditions (pH 7.4, m-cresol, high surfactant concentration) the protein is most likely to persist 
in a dimeric self-association state [19, 23, 24].  For the formation of a dimer, the extended C-
terminus of the B-chain (B24 - B30) engages in intermolecular hydrophobic interactions 
forming a two-stranded anti-parallel β-sheet [20, 21, 24] (Fig. 6).  However, the presence of 
phenols, such as m-cresol, may affect the confirmation of the N-terminus of the B-chain, which 




) [18, 20].  The extended 
B1-B9 strand may undergo a coil-to-helix conversion (Fig. 6), which would leave the histidine 
residues buried within the phenolic pockets [19]. 
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The h-ACTH fragment (18-39) that was used as a histidine-free peptide (control) did 
not co-polymerize with ethyl- and butylcyanoacrylate, as expected (Fig. 3a).  Interestingly the 
small histidine-free IGF-1 (1-3) fragment Gly-Pro-Glu did co-polymerize with both PECA 
(Fig. 3b, Fig. 4) and PBCA (data not shown).  The C-terminal glutamic acid was identified as 
the site of interaction in IGF-1(1-3), which suggests an anionic reaction pathway.  It is unclear 
whether the modification occurs at the C1 carboxyl-end or the carboxyl-group of the side chain.  








 in h-ACTH (18-39) nor 




]-angiotensin II and h-ACTH (18-39) were 
identified as sites of modification by acrylates in our experiments, suggesting that in IGF-1(1-
3) the C-terminal position of Glu provokes reactivity towards PECA and PBCA. Glutamic acid 
has a pKa1 of 2.1 for the C1 carboxylic acid and a pKa2 of 4.07 for the side chain carboxylic 
acid.  Controlling the pH in the polymerization medium should have enabled selective 
deprotonation, hence activation, of either carboxylic acid.  In our studies, however, lowering 
the pH of the polymerization medium to pH 1.9 below the pKa1 of glutamic acid did not 
prevent the co-polymerization of glutamic acid with PACA (Fig. 5b).  Internal glutamic acids 








 in h-ACTH (18-
39) were not modified.  This could be an indication that only C-terminal glutamic acids react, 
which in turn would suggest the C1 carboxylic acid to be the site of modification.  H
1
-NMR 
studies could be employed to clarify the exact site of modification within the glutamic acid 
residue.  Other free C-termini such as phenylalanine (Phe
22
 in h-ACTH (18-39)) or threonine 
(Thr
B30
 in insulin), however, seem less reactive towards PACA in an in situ polymerization as 
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compared to the C-terminal glutamic acid Glu
3
 in IGF-1 (1-3) or strong nucleophiles, such as 








The outcome of this study has various implications on applications using PACA 
nanoparticles.  An expert opinion article by Graf et al. [25] recently pointed out the problems 
potentially associated with PACA nanoparticles due to their high variability in entrapment, 
release, and covalent interference of protein and peptide drugs in the polymerization process.  
The need to overcome those challenges and to optimize and control critical formulation 
parameters is mandatory for the successful introduction of PACA nanoparticles to the 
pharmaceutical market [25].  This present study is further raising concern about (i) the potential 
of various amino acid residues to co-polymerize with PACA nanoparticles and (ii) the little 
control there may be over the extent of co-polymerization by adjusting parameters such as the 
pH.  For co-polymerized formulations, every co-polymer comprises a new potentially bioactive 
compound and requires full characterization and FDA approval/registration etc.  Non-co-
polymerized pharmaceutical formulations containing PACA need to be screened using 
technology such as MALDI TOF mass spectrometry to exclude co-polymerization and to verify 
their safety and suitability for the pharmaceutical market.  For those systems, however, 
additional in vivo studies would have to demonstrate the absence of co-polymerization in the 
abundance of endogenous, physiological proteins and peptides. 
 
5.  CONCLUSIONS 
 21 
 
The covalent interference of protein and peptide drugs depends on more than one key 
factor.  Interference may take place via anionic or zwitter-ionic pathways involving amino acid 
residues such as histidine (zwitter-ionic pathway) or C-terminal glutamic acid (anionic 
pathway).  The likelihood of interference seems highly dependant on the complexity and size of 
the molecule and the sterical availability of the reactive site.  Tandem MALDI TOF/TOF mass 
spectrometry is an ideal technology for the characterization of components of PACA 
nanoparticles and identification of covalent drug/polymer interactions on the molecular level.  
Co-polymerization of peptide drugs with PACA is a phenomenon to be cognizant of when 
designing pharmaceutical delivery systems and the ability to reliably detect co-polymerization 
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